Is Bionomics Limited (BNOEF) a Buy, Sell, or Hold?
OTC : BNOEF
Bionomics Limited
$0.006 USD
$0.0 (-14.29%)
- Volume
- 72.74K
- Average Volume
- 91.4K
- Market Capitalization
- $8.81M
- P/E Ratio
- -0.30
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.06
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $14.31
Company Overview
OTC
Spyridon Papapetropoulos
Biotechnology
Healthcare
BNOEF
N/A
AU
USD
Liquidity Metrics
0.00
14.31
14.31
12.85
0.00
Sales & Valuation
-$
-1.72
0.61
0.30
10.99
Profitability
-$0.01
-$15.49B
271.97%
274.64%
-113.35%
-81.82%
P/E Metrics
-0.30
0.01
0.01
Analyst Price Target & Rating
0/5
3 Analysts
%
Financial Health Scores
-5.64
7/9
$15.54M
$30.71M
$4.72M
-$5.9M
Key Metrics (TTM)
-$1.57M
0.15
0.07
14.31
-113.35%
-71.97%
-159.50%
333.41%
-332 days
Company Executives
| Name | Title |
|---|---|
| Timothy Cunningham | Chief Financial Officer |
| Atul R. Mahableshwarkar | Acting Chief Medical Officer |
| Julie Kerner | Senior Vice President of Bus. Operations |
| Adrian Hinton | Financial Controller |
Poll Results
No votes yet today — be the first to share your view!
About Bionomics Limited (OTC:BNOEF) Stock
Bionomics Limited, an Australian clinical-stage biopharmaceutical company founded in 1996 and based in Eastwood, focuses on identifying and developing innovative drug candidates to address central nervous system conditions and various cancers. A significant experimental medicine in their pipeline is BNC210, a negative allosteric modulator targeting the a7 nicotinic acetylcholine receptor. This compound is currently undergoing a Phase 2 clinical trial for social anxiety disorder and a Phase 2b study for post-traumatic stress disorder (PTSD). The company's portfolio also includes BNC101, a monoclonal antibody designed to combat cancer stem cells, which has successfully completed its Phase 1 clinical evaluation. Additionally, Bionomics is advancing BNC105, currently in a Phase 2 clinical tria ... l for refractory colorectal cancer and a Phase 1 trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.
Frequently Asked Questions
-
What is the current Bionomics Limited (BNOEF) stock price?
-
Bionomics Limited(OTC:BNOEF) stock price is $0.006 in the last trading session. During the trading session, BNOEF stock reached the peak price of $0.055 while $0.0013 was the lowest point it dropped to. The percentage change in BNOEF stock occurred in the recent session was --14.29% while the dollar amount for the price change in BNOEF stock was -$0.0.
-
BNOEF's industry and sector of operation?
-
The OTC listed BNOEF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BNOEF?
-
Timothy Cunningham | Chief Financial Officer
Atul R. Mahableshwarkar | Acting Chief Medical Officer
Julie Kerner | Senior Vice President of Bus. Operations
Adrian Hinton | Financial Controller
| -
How many employees does BNOEF have?
-
Number of BNOEF employees currently stands at None. BNOEF operates from 200 Greenhill Road, Eastwood, SA 5063, AU.
-
Link for BNOEF official website?
-
Official Website of BNOEF is: https://www.bionomics.com.au
-
How do I contact BNOEF?
-
BNOEF could be contacted at phone #61 8 8150 7400 and can also be accessed through its website. BNOEF operates from 200 Greenhill Road, Eastwood, SA 5063, AU.
-
How many shares of BNOEF are traded daily?
-
The average number of BNOEF shares traded daily for last 3 months was 91.4K.
-
What is the market cap of BNOEF currently?
-
The market value of BNOEF currently stands at $8.81M with its latest stock price at $0.006